Press Releases

The Truveta Genome Project will enable scientists to transform how diseases are prevented, diagnosed and cured.

Health care venture capital firm Allumia Ventures has spun off from Providence to become an independent venture capital firm following a first close of its third fund.

Providence announced plans to sell 10 skilled nursing and assisted living care ministries. The sale will ensure continued access to these vital services in its communities.

Catch the 2024 highlights from Providence Cancer Institute in this year-end recap focused on research advancements, caregiver recognition and community engagement.

Discover how Dean Lookingbill’s battle with lymphoma led him to CAR T-cell therapy at Providence Cancer Institute.

Providence announced results for the three months ended September 30, 2024. The not-for-profit health system continued to improve performance while serving more people in need.

Two global studies open at Providence Cancer Institute will evaluate combinations of medications to help stop or slow the growth of cancer in solid tumors.

Providence selects Darryl A. Elmouchi, M.D., MBA, as its new chief operating officer, effective Jan. 2.

Real-world data from Providence, Illumina and Microsoft Research finds cancer patients with early genomic testing received better precision treatment, underlines urgency to become standard practice

Health Connect Partners (HCP), Providence's Medicare Shared Savings Program (MSSP) Accountable Care Organization (ACO), generated more than $137 million in savings to CMS in 2023.

New study evaluates a type of CAR T-cell therapy called liso-cel. Researchers will collect data from multiple groups in a study that may give patients hope for long-term remission and quality of life.

Explore promising clinical trials at Providence Cancer Institute that are investigating immunotherapy for early-stage TNBC and high-risk, HR-positive breast cancer.